Scarica l'app Stockscreener
87.56
2.07%
-1.85
Pre-mercato:
87.05
-0.51
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$89.41
Aprire:
$88.71
Volume 24 ore:
1.41M
Relative Volume:
0.60
Capitalizzazione di mercato:
$16.94B
Reddito:
$8.41B
Utile/perdita netta:
$760.80M
Rapporto P/E:
22.74
EPS:
3.8513
Flusso di cassa netto:
$1.05B
1 W Prestazione:
+4.03%
1M Prestazione:
+0.33%
6M Prestazione:
-6.93%
1 anno Prestazione:
-6.32%
Intervallo 1D:
$87.50
$88.78
Intervallo di 1 settimana:
$84.32
$91.84
Portata 52W:
$79.12
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Nome
Zimmer Biomet Holdings Inc
Settore
Industria
Telefono
(574) 267-6131
Indirizzo
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
87.56 | 16.94B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
95.18 | 165.79B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.85 | 125.30B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.01 | 104.98B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.81 | 66.60B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
93.64 | 53.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-02-20 | Iniziato | William Blair | Mkt Perform |
| 2026-01-09 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Aggiornamento | Roth Capital | Neutral → Buy |
| 2024-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Iniziato | Wolfe Research | Peer Perform |
| 2024-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-21 | Aggiornamento | Argus | Hold → Buy |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Iniziato | ROTH MKM | Neutral |
| 2023-08-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-05-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-03-29 | Iniziato | UBS | Sell |
| 2023-03-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Underweight |
| 2022-10-12 | Iniziato | Jefferies | Underperform |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-04-01 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Underperform |
| 2022-03-02 | Downgrade | Loop Capital | Buy → Hold |
| 2022-02-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Reiterato | Citigroup | Buy |
| 2022-02-08 | Reiterato | Deutsche Bank | Hold |
| 2022-02-08 | Reiterato | JMP Securities | Mkt Outperform |
| 2022-02-08 | Reiterato | JP Morgan | Neutral |
| 2022-02-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Reiterato | Stifel | Buy |
| 2022-02-08 | Reiterato | Truist | Buy |
| 2022-02-08 | Reiterato | UBS | Neutral |
| 2022-02-08 | Reiterato | Wells Fargo | Underweight |
| 2022-02-02 | Downgrade | UBS | Buy → Neutral |
| 2022-01-19 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Downgrade | Needham | Strong Buy → Buy |
| 2021-12-07 | Iniziato | Loop Capital | Buy |
| 2021-11-23 | Downgrade | Argus | Buy → Hold |
| 2021-09-14 | Ripresa | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-09 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Reiterato | Needham | Strong Buy |
| 2020-10-20 | Iniziato | Northland Capital | Market Perform |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-08-05 | Reiterato | Needham | Strong Buy |
| 2020-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Reiterato | Needham | Strong Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-09-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Aggiornamento | Argus | Hold → Buy |
| 2019-07-30 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Aggiornamento | Needham | Buy → Strong Buy |
Mostra tutto
Zimmer Biomet Holdings Inc Borsa (ZBH) Ultime notizie
Zimmer Biomet focuses on orthopedic growth. Investors watch long-term demand - Ad-hoc-news.de
Zimmer Biomet (ZBH) Coverage Initiated with Market Perform Ratin - GuruFocus
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zimmer Biomet To Acquire Iovera Pain Therapy Business For $140M - InkFreeNews.com
Zimmer Biomet focuses on orthopedic growth as investors weigh long-term demand - AD HOC NEWS
Zimmer Biomet stock holds focus on execution - AD HOC NEWS
Evercore ISI Adjusts Price Target on Zimmer Biomet to $110 From $120 - Moomoo
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Zimmer Biomet stock holds steady on thin coverage. Focus stays on execution. - AD HOC NEWS
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
JP Morgan Downgrades Zimmer Biomet Holdings (ZBH) - MSN
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating the Potential 12.84% Upside in the Healthcare Sector - DirectorsTalk Interviews
Enterprise value to revenue forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Stock Looks Cheap On Earnings But Faces Growth Doubts - Sahm
Zimmer Biomet Holdings Inc (ZBH) Shares Surge 3.9% -- What GF Sc - GuruFocus
Zimmer Biomet (ZBH) director awarded 389 Phantom Stock Units in deferred pay plan - Stock Titan
[Form 4] ZIMMER BIOMET HOLDINGS, INC. Insider Trading Activity - Stock Titan
Form 4 Zimmer Biomet Holdings Inc For: 2 July By Investing.com - Investing.com India
Zimmer Biomet (ZBH) director granted 317.369 cash-settled phantom stock units - Stock Titan
Zimmer Biomet (ZBH) director awarded 317.369 phantom stock units in cash-settled plan - Stock Titan
Phantom stock grant increases Zimmer Biomet (NYSE: ZBH) director units - Stock Titan
Zimmer Biomet (NYSE: ZBH) director receives cash-settled phantom stock grant - Stock Titan
Zimmer Biomet (ZBH) director receives new phantom stock unit award - Stock Titan
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India - marketscreener.com
Enterprise value to EBIT forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity - Yahoo Finance
Zimmer Biomet Holdings | SD: Specialized disclosure report - Moomoo
‘Cool move’ by Zimmer part of med-tech’s tuck-in deals trend - BioWorld News
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
BTIG Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating - Moomoo
Persona IQ from Zimmer Biometsmart knee implant brings continuous data to US surgeons - AD HOC NEWS
A Look at Zimmer Biomet Holdings Inc (ZBH) After 5.6% Decline -- GF Value $126.11 vs Price $86.09 - GuruFocus
Zimmer Biomet Holdings, Inc.'s Stock Price Plummets to $86.09, Suffers a Sharp 5.64% Drop - Smartkarma
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MSN
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Why is Zimmer Biomet stock sliding today? By Investing.com - Investing.com Canada
What is behind Zimmer Biomet stock's recent drop in value today - Traders Union
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
Zimmer Biomet secures $2.75 billion credit, shares under Wall Street scrutiny - AD HOC NEWS
Zimmer Biomet Holdings (ZBH) Secures New Credit Agreements to Bo - GuruFocus
The Persona Knee System from Zimmer Biomet Holdings Inc.modular design tailored to each joint - AD HOC NEWS
Is Zimmer Biomet stock underperforming the S&P 500? - MSN
Zimmer Biomet Holdings Inc Azioni (ZBH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.74%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):